Allergic Asthma at a High Exacerbation Rate: Omalizumab or Dupilumab First
A biologic-naive patient eligible for either of two drugs by every standard criterion, with the decision actually turning on how CHEST's own algorithm reads his exacerbation history.
Marcus T. drives a forklift on the overnight shift at a regional distribution warehouse, a building he describes, without much exaggeration, as “wall-to-wall cardboard dust and whatever’s living in it.” His asthma dates back to early childhood, always tied to the same triggers — dust mites at home, the neighbor’s cat, ragweed every fall — and for most of his twenties it stayed background noise. This year it stopped staying quiet: two emergency department visits and one overnight admission, the most recent four weeks ago, all despite a regimen his pulmonologist had already pushed to high-dose inhaled corticosteroid and long-acting beta-agonist plus montelukast.
He is, on paper, eligible for either of the two biologics his allergy history points toward. His total IgE of 450 IU/mL and 78 kg body weight sit comfortably inside omalizumab’s dosing table, and his perennial sensitization to dust mite and cat dander is exactly the profile the drug was built around — the kind of case that, a few years ago, would not have generated much discussion at all. But CHEST’s 2026 guideline does not leave first-choice-between-the-two open-ended for a patient like him — it frames the omalizumab-versus-dupilumab decision specifically around exacerbation frequency, and its stated criterion — two or more exacerbations a year, or any severe exacerbation requiring hospitalization — is one he meets on both counts at once, with three events in twelve months and an inpatient admission among them, the burden its algorithm treats as evidence that a more potent starting point is worth the tradeoff, rather than defaulting to the older, more familiar drug and revisiting the question only after it has already failed him once. His most recent admission came four weeks ago, close enough that the decision in front of the team is not abstract: whatever gets started this visit needs to actually hold through his next dust-heavy shift, not just look reasonable on his chart.
Choosing a first biologic before the next exacerbation
His allergy profile is about as clean a match for omalizumab as I see — perennial dust mite and cat sensitization, an IgE and weight combination that lands well inside the dosing table, and this is the drug with the longest track record in exactly this phenotype. I would start there and reserve dupilumab for if it does not hold.
I do not disagree that omalizumab fits his allergy profile. What I would weight more heavily is that CHEST does not leave this an open pharmacologic preference for a patient like him — its own guideline frames the choice between these two agents specifically around exacerbation frequency, and three events in a year with one hospitalization clears its stated bar — two or more exacerbations annually, or any severe exacerbation requiring hospitalization — on both counts rather than one.
A clean allergy match is a real signal, but it is the signal the guideline had in front of it when it still wrote frequency, not phenotype, as the deciding factor for a patient sitting where he does.
If the pharmacology genuinely favors dupilumab here, I do not want to relitigate that — but I want it said plainly that this decision also carries a real access dimension for him: a warehouse overnight-shift worker with unpredictable hours, weighing an every-two-week injection schedule against whatever his plan’s prior-authorization timeline looks like for each drug. That is not a reason to override the clinical read. It is a reason to make sure the choice actually gets started this visit rather than stalling in an authorization queue while he has a fourth exacerbation waiting.
Agreed: start dupilumab this visit rather than omalizumab, on the exacerbation-frequency reading of CHEST's algorithm, with prior authorization submitted same-day and a bridging plan discussed if it is delayed.
The allergist's read was not overruled so much as set aside for now — explicitly framed as the option to return to if dupilumab underperforms, rather than a settled judgment that it was the wrong first choice on the merits.